Published: November 12, 2025
Summary:
- WeightWatchers says it plans to sell Novo Nordisk’s forthcoming Wegovy pill in the U.S., likely after a 2026 launch, sharpening its push into branded anti‑obesity treatments. [1]
- Sandoz expects unbranded versions of Ozempic to reach Canada by end‑June 2026, adding fresh price pressure to semaglutide markets outside the U.S. [2]
- U.S. payer dynamics remain fluid: CVS removed Lilly’s Zepbound from a preferred list while retaining Novo’s Wegovy, and Lilly is shifting its employees away from CVS, according to Reuters. [3]
- NVO shares recently traded at $49.76 (19:38 UTC), up modestly intraday.
WeightWatchers says it will sell Wegovy in a pill once launched
WeightWatchers (WW) plans to carry Novo Nordisk’s oral Wegovy, pending U.S. approval, leaning into consumer preference for pills over injections and differentiating from rivals pushing cheaper copycat products. The move follows the company’s bankruptcy exit and dovetails with a broader U.S. pricing framework announced last week that targets lower monthly costs for GLP‑1 therapies. [4]
Why it matters: Convenience could further expand GLP‑1 adoption. The White House’s fact sheet outlines headline pricing—$150/month for starter doses of weight‑loss pills through TrumpRx if approved, and $245/month for injectables like Wegovy under Medicare/Medicaid, alongside Novo’s $10 billion U.S. investment that includes producing the Wegovy tablet domestically. Those levers could broaden access and speed the oral market’s ramp. [5]
Canada prepares for Ozempic copies, raising competitive stakes
Sandoz’s chief executive said unbranded (biosimilar) versions of Ozempic could launch in Canada by the end of June 2026, following semaglutide patent expiries. He cautioned that supply will likely be constrained, but Canada will serve as a crucial “testing ground” for cheaper GLP‑1s used in diabetes—medicines that share the same active ingredient as weight‑loss drug Wegovy. U.S. patents still run into the next decade, insulating Novo’s domestic franchise for now. [6]
Payers reshuffle coverage amid price deals
In the latest U.S. access twist, Eli Lilly will drop CVS’s drug plan for its employees after CVS stopped covering Lilly’s Zepbound in favor of Novo’s Wegovy, reflecting aggressive formulary negotiations and the downstream effects of the new federal pricing arrangement. CVS says it still offers options that cover both drugs, but at higher cost for plan sponsors than its standard formulary. [7]
Backdrop: Novo’s agreement with the Administration points to $149/month starter prices for pills (if approved) and $245/month for injectables under Medicare/Medicaid, with Novo also committing to expanded U.S. manufacturing. Novo has warned of a negative low single‑digit impact to 2026 global sales growth as lower prices meet broader access. [8]
Market check: NVO edges higher
By early evening in London (19:38 UTC), NVO traded at $49.76, having ranged between $49.27–$50.41 intraday as investors weighed the day’s access developments and competitive signals.
The bigger picture for investors
Today’s headlines show how Novo is working both top‑down (policy & pricing) and bottom‑up (partners & channels) to defend and expand GLP‑1 access:
- Channel expansion: WeightWatchers aligning to sell the oral Wegovy strengthens branded distribution beyond retail pharmacies and telehealth. [9]
- International pressure: Canada’s path to unbranded semaglutide spotlights medium‑term price compression outside the U.S., even as American patents hold through 2032. [10]
- U.S. coverage momentum: The Administration’s pricing framework amounts to a de‑facto coverage unlock for anti‑obesity medicines, with potential volume offsets to price cuts if execution and supply hold. [11]
What’s next to watch
- FDA timelines for oral Wegovy and rival oral GLP‑1s (fast‑track review is being considered). [12]
- Formulary shifts across PBMs and employer plans as the TrumpRx pricing scheme is implemented. [13]
- Canada’s regulatory milestones for unbranded semaglutide and early demand signals once launched. [14]
Sources: Reuters reporting on WeightWatchers’ plans for Wegovy pill and U.S. payer developments; Reuters interview with Sandoz’s CEO on Canada timing; White House fact sheet on GLP‑1 pricing and manufacturing commitments; real‑time pricing via market data. [15]
Ticker: NYSE: NVO
References
1. www.reuters.com, 2. www.reuters.com, 3. www.reuters.com, 4. www.reuters.com, 5. www.whitehouse.gov, 6. www.reuters.com, 7. www.reuters.com, 8. www.whitehouse.gov, 9. www.reuters.com, 10. www.reuters.com, 11. www.whitehouse.gov, 12. www.reuters.com, 13. www.whitehouse.gov, 14. www.reuters.com, 15. www.reuters.com
